Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oligonucleotide compositions and their use to induce differentiation of cells

a technology of oligonucleotide compositions and compositions, which is applied in the direction of drug compositions, peptide/protein ingredients, extracellular fluid disorders, etc., can solve the problems of reduced oxygen delivery to cells, reduced immune function, and insufficient production of cells destined to become erythrocytes or granulocytes, so as to increase the number of bone marrow derived cells, and restore the effect o

Inactive Publication Date: 2007-01-11
BIONICHE LIFE SCI
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides a method for treating diseases associated with growth of cells that are not differentiated to a mature phenotype. The method involves administering a composition containing a specific sequence of nucleotides that induces differentiation of cells. The composition can be used to treat leukemia, lymphoma, and other blood disorders. The method can also be used in combination therapy with other therapeutic modalities such as chemotherapy, radiation therapy, and immunotherapy. The composition can also be used to stimulate production of cells after other therapies have depleted such cells. The invention provides an important benefit for animals and humans by inducing differentiation of cells that are not normally differentiated."

Problems solved by technology

Insufficient production of cells destined to become erythrocytes or granulocytes is associated with numerous problems, including but not limited to, reduced delivery of oxygen to cells, decreased immune function, and clotting abnormalities.
Various therapies, including expensive chemotherapies, are often required to stimulate production of red and white cells.
Most prior art differentiating therapies have proven to be less than adequate for clinical applications.
Many of these therapies are inefficient or toxic, have significant adverse effects and are debilitating for the recipient.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Sequences

[0060] Phosphodiester nucleotide sequences (SEQ ID NOs: 1, 2, 3 and 4) were prepared by Sigma-Genosys (Woodlands, Tex.) using Abacus Segmented Synthesis Technology. Unless stated otherwise, the sequences were dispersed in autoclaved deionized water or in a pharmaceutically acceptable buffer such as, but not limited to, saline immediately prior to use.

example 2

Cells

[0061] The K562 cell line derived from the leukemic cells of a CML patient in blastic crisis is used as the standard model for determining, in vitro, the therapeutic potential of new differentiating compounds (Rutherford et al., Nature, 280:164, 1979; Drexler et al. DSMZ Catalogue of Human and Animal Cell Lines, 6th ed., Braunschweig, Germany: DSMZ, 1997). K562 cells were obtained from the American Type Culture Collection (ATCC, Rockville, Md.) and were cultured in the medium recommended by the ATCC.

example 3

Hemoglobin Synthesis by K562 Cells Cultured with SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO: 3 and SEQ ID NO: 4.

[0062] K562 cells were seeded in 1.0 ml at 2.0×105 cells / ml in 6-well flat-bottomed tissue culture plates for 72 hours with 100 μg of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. For hemoglobin determination, the cells were washed twice by centrifugation in phosphate-buffered saline (PBS), stained with 0.2% benzidine (Sigma-Aldrich Canada, Oakville, Ontario) in 0.5 M acetic acid activated with 10% H2O2 (Gambari et al., Experimentia 41:673, 1985). After 10 minutes incubation in the dark, the percentages of benzidine positive cells (hemoglobin positive cells) were determined by light microscopy using an hemocytometer. Approximately 500 cells were counted for the determination of the percentages of benzidine positive cells. Cell size was also determined by light microscopy. Hemin (20 μg) was added to K562 cells for 72 hours as a control for hemoglobin synthesis. Hem...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
compositionsaaaaaaaaaa
compositionaaaaaaaaaa
Login to View More

Abstract

The present invention provides compositions comprising a 3′-OH, 5′-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce differentiation of cells or to stimulate differentiation or production of pluripotent cells. The present invention provides methods of using these compositions to induce differentiation of pluripotent cells, including bone marrow derived cells, and to treat disease associated with insufficient differentiation of cells in animals and humans, including but not limited to leukemia, lymphoma, non-malignant blood disorders such as hemoglobinopathies, sickle cell disease, myelodysplastic syndrome, pancytopenia, anemia, thrombocytopenia and leukopenia.

Description

PRIOR RELATED APPLICATIONS [0001] The present application claims priority to U.S. provisional patent application Ser. No. 60 / 286,158 filed Apr. 24, 2001. This application is a divisional of U.S. patent application Ser. No. 10 / 127,645 filed Apr. 22, 2002, now allowed, the contents of which are incorporated herein by reference.SEQUENCE LISTING [0002] The content of the sequence listing information is identical to the paper sequence listing provided in U.S. patent application Ser. No. 10 / 127,645 filed Apr. 22, 2002, and includes no new matter. FIELD OF THE INVENTION [0003] The present invention provides compositions comprising specific oligonucleotides combined with a pharmaceutically acceptable carrier, wherein the compositions are useful to induce differentiation of cells, including pluripotent cells, leukemic cells, lymphoma cells and bone marrow-derived cells, and to treat diseases such as leukemia, lymphoma and disorders associated with insufficient differentiation of cells. BACKG...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K48/00C07H21/04A61K31/7088A61K31/7105A61K38/00A61P7/00A61P7/06A61P35/00A61P35/02A61P43/00C12N15/117
CPCA61K31/7105C12N2310/18C12N15/117A61K38/00A61P35/00A61P35/02A61P43/00A61P7/00A61P7/06
Inventor FILION, MARIO C.PHILLIPS, NIGEL C.
Owner BIONICHE LIFE SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com